Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1731656

registered interest
date	07/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to secure funding for and expand access to minimally invasive cancer therapies approved by the National Institute for Health and Care Excellence across NHS Trusts.
tabling member printed	Baroness Finlay of Llandaff
uin	HL1205
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>Both NHS England and integrated care boards (ICBs) are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by the National Institute for Health and Care Excellence (NICE).</p><p>Where treatments are approved by NICE through the Technology Appraisals programme, the National Health Service is required to fund and make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.</p><p>During 2024/25, NHS England will continue to support all ICBs in integrating the planning and commissioning of suitable specialised services with their wider population-level commissioning responsibilities, in line with their individual timeline for delegation. Service Development Funding (SDF) is available to support Cancer Alliances to deliver the priorities set out in the 2024/25 NHS Operational Planning Guidance; £266 million in SDF is being provided to Cancer Alliances in 2024/25. Funding comprises two allocations: place-based, provided to all Alliances on a fair shares basis; and, targeted, provided to a selection of Alliances for agreed targeted projects. Cancer SDF is provided to Cancer Alliances via their lead ICBs to enable them to deliver on NHS-wide priorities for cancer, in line with their local delivery plans which are included in their funding agreement.</p> answering member printed Baroness Merron question first answered 11/10/2024 13:26:54 answering member 347 label Biography information for Baroness Merron
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1731657

registered interest
date	07/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that NHS Trusts have the necessary funding and trained staff to deliver minimally invasive cancer therapies.
tabling member printed	Baroness Finlay of Llandaff
uin	HL1206
answer	answer is ministerial correction date of answer 16/10/2024 answer text <p>The adoption of new treatments, including increasing the number and availability of minimally invasive cancer treatments, into the National Health Service in England is generally the result of National Institute for Health and Care Excellence (NICE) guidance and commissioner decisions. Both NHS England and the integrated care boards (ICBs) are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by the NICE.</p><p>Where treatments are approved by the NICE through the Technology Appraisals programme, the NHS is required to fund and make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.</p><p>During 2024/25, NHS England will continue to support all ICBs in integrating the planning and commissioning of suitable specialised services with their wider population-level commissioning responsibilities, in line with their individual timeline for delegation.</p><p>We are committed to training the staff we need to get patients seen on time. The Government will make sure the NHS has the staff it needs to be there for all of us when we need it, including cancer patients.</p> answering member printed Baroness Merron question first answered 16/10/2024 12:07:37 answering member 347 label Biography information for Baroness Merron
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1726524

registered interest
date	02/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Home Care Services: Prescriptions
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what evidence they have of unrelieved symptom distress in patients when care assistants are prohibited from administering prescribed medication at home; and how many errors have been recorded when care assistants have administered prescribed breakthrough medication in the patient's home.
tabling member printed	Baroness Finlay of Llandaff
uin	HL596
answer	answer is ministerial correction date of answer 09/09/2024 answer text <p>Good practice for homecare is set out in the National Institute for Health and Care Excellence’s (NICE) guidance, which can be found on the NICE’s website, in an online only format.</p><p>Services need to submit statutory notifications to the Care Quality Commission (CQC) when a medicines incident reaches a specific threshold. This includes an allegation of abuse, the death of a person, an incident reported to or investigated by the police, or a serious injury.</p><p>Data on anything that does not constitute the CQC threshold is not held by the CQC, but may be held by individual providers as a recorded incident.</p> answering member printed Baroness Merron question first answered 09/09/2024 16:37:42 answering member 347 label Biography information for Baroness Merron
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1713986

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of new data from the Office for National Statistics showing that alcohol-specific deaths are now 32.8 per cent higher than in 2019 and at an all-time high; and what steps they plan to take to tackle rising alcohol harm.
tabling member printed	Baroness Finlay of Llandaff
uin	HL4093
answer	answer is ministerial correction date of answer 07/05/2024 answer text <p>The Government keeps all official health data related to alcohol consumption and alcohol related harms under regular review. The 2021 Public Health England publication, Monitoring alcohol consumption and harm during the COVID-19 pandemic, found that increases in alcohol consumption since the beginning of the pandemic tended to be among people who were already heavy drinkers before this period, which may be a factor in the increase.</p><p> </p><p>The most effective way to prevent alcohol specific deaths, is drinking within the United Kingdom Chief Medical Officers’ low-risk drinking guidelines, namely under 14 units per week. The Government is supporting people who drink above low-risk levels to reduce their alcohol consumption. As part of the NHS Health Check, questions are asked about alcohol consumption, and appropriate advice given to support people to make healthier choices. Those identified to be drinking at higher-risk levels are referred for liver investigation. The Department is also supporting people with alcohol dependency through the Drug Strategy and NHS Long Term Plan, by facilitating more people in need of treatment into local authority commissioned alcohol treatment services.</p> answering member printed Lord Markham question first answered 07/05/2024 12:38:31 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1713987

registered interest
date	25/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alcoholic Drinks: Labelling
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they plan to take to meet their 2020 commitment to a consultation on alcohol calorie labelling.
tabling member printed	Baroness Finlay of Llandaff
uin	HL4094
answer	answer is ministerial correction date of answer 08/05/2024 answer text <p>The Government has previously announced an intention to consult on whether to introduce mandatory calorie labelling on alcohol. We are currently considering the evidence base, and have commissioned a National Institute for Health and Care Research study on understanding the impact of alcohol calorie labelling on alcohol and calorie selection, purchasing, and consumption.</p><p>The Government is taking a wide-ranging approach to addressing alcohol-related harms. As part of the NHS Health Check, information on alcohol consumption is provided to support people to make healthier choices. The Department continues to promote the United Kingdom’s Chief Medical Officers’ Low Risk Drinking Guidelines in England through online platforms. This provides the public with the most up-to-date scientific information, to help people make informed decisions about their own drinking, including the health harms of alcohol consumption.</p> answering member printed Lord Markham question first answered 08/05/2024 15:06:15 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1701610

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what progress they have made with the proposed amendments to the Part IX of the Drug Tariff, including any impact assessments on the future provision of medical technologies in the UK; how these proposals meet the ambitions of the Life Sciences Vision; and what steps they are taking to ensure that there is sufficient patient choice following the outcome of the consultation.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3841
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3842 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1701611

registered interest
date	16/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3842
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p> answering member printed Lord Markham grouped question UIN HL3841 question first answered 22/04/2024 15:04:52 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700674

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tofersen: Licensing
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3732
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3733 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1700675

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tofersen
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.
tabling member printed	Baroness Finlay of Llandaff
uin	HL3733
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> answering member printed Lord Markham grouped question UIN HL3732 question first answered 22/04/2024 15:05:49 answering member 4948 label Biography information for Lord Markham
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1687664

registered interest
date	05/02/2024
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Incontinence: Men
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether the needs of men who are incontinent, but not classified as disabled as defined under the Equality Act 2010, are recognised and provided for with appropriate facilities to dispose of sanitary pads under the Workplace (Health, Safety and Welfare) Regulations 1992, and the Approved Code of Practice; and when they plan to next review the Approved Code of Practice.
tabling member printed	Baroness Finlay of Llandaff
uin	HL2186
answer	answer is ministerial correction date of answer 12/02/2024 answer text <p>The Health and Safety Executive (HSE) are reviewing the Approved Code of Practice (ACOP) and guidance of the Workplace (Health, Safety and Welfare) Regulations 1992 regarding provision of disposal facilities in workplace toilets only, to ensure they meet the needs of both men and women. There will be a public consultation on any changes in summer 2024 and the updated ACOP and guidance will be published in spring 2025.</p><p> </p><p>HSE is the workplace regulator, therefore the legislation and guidance will only apply to toilets for use by workers in workplaces, made available to them as a place of work.</p> answering member printed Viscount Younger of Leckie question first answered 12/02/2024 16:14:39 answering member 4169 label Biography information for Viscount Younger of Leckie
tabling member	3609 label Biography information for Baroness Finlay of Llandaff